CellSource
Basic Information
- Stock Code
- 4880
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- November 2015
- Listing Year
- October 2019
- Official Website
- https://www.cellsource.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- GNI Group, Heartseed, Port to Win Holdings, Celsys, NeoJapan, Open Door, Ubicom Holdings, Sun Asterisk, Link-U Group, Nexel Pharma, PeptiDream, SanBio, Helios, Rena Science, QualiPs, Takara Bio, Japan Material, Macbee Planet, Direct Marketing Mix, Japan Tissue Engineering
Overview
CellSource is a bio-venture founded in 2015 in the regenerative medicine field, with its main businesses being outsourced services for culturing adipose-derived stem cells and regulatory compliance support, and it is a leading company in the industry listed on the Tokyo Stock Exchange Prime Market.
Current Situation
CellSource recorded net sales of approximately 4.51 billion yen and operating profit of approximately 1.22 billion yen in fiscal year 2023, maintaining profitable operations. Centering on its main business of outsourced adipose-derived stem cell processing services, it has partnered with over 1,800 medical institutions in orthopedics, plastic surgery, obstetrics, and gynecology to expand its business. In October 2023, it changed its market segment to the Tokyo Stock Exchange Prime Market. Its strengths include proprietary cell processing technology and high expertise in regulatory compliance support, and it conducts numerous joint research projects with universities and research institutions. In recent years, it has promoted partnerships with sports teams and introduced egg freezing services as corporate welfare benefits. It is actively pursuing new businesses such as expansion into animal medicine and development of biotherapy insurance, advancing sustainable growth and technological innovation. In the medium to long term, it aims to diversify its service areas and expand internationally along with the growth of the regenerative medicine market.
Trivia
Interesting Facts
- Bio-venture that listed on TSE Mothers just 4 years after founding
- Overwhelming number of partnerships in orthopedic regenerative medicine services
- Concluded medical partner contracts with numerous sports organizations
- Achieved efficient cell processing with proprietary central kitchen model
- Co-developed skincare products with YouTuber Hikaru
- Ongoing joint research on regenerative medicine technology for animal medicine
- Developed industry-first biotherapy insurance with Sumitomo Life
- Obtained MHLW approval for specific cell processed product manufacturing
- Profitable operations with active R&D investment from profits
- Introduced women's egg freezing storage service as corporate welfare
- Multiple joint research projects with Jichi Medical University and Juntendo University
- Paid-in capital of approximately 1.4 billion yen, outstanding shares approximately 20 million
- Expanded beyond orthopedics into plastic surgery and infertility treatment
- Changed market segment to TSE Prime in 2023
- Growth through outsourcing businesses for stem cell and blood processing
Hidden Connections
- Provides egg freezing to welfare benefits services of major companies like Itochu Corporation
- Co-developing regenerative medicine-related insurance products with Sumitomo Life Group
- Provides medical support to B.League basketball and J1 soccer clubs
- Business partnership with Fuji Pharma for women's medical business
- Selected as member of Osaka Prefecture's Future Medical Promotion Organization, strengthening regional ties
- Co-developed cosmetics with YouTuber Hikaru to appeal to younger demographics
- Business partnership with largest animal medical insurer Anicom for technology and insurance services
- Joint research survey on knee osteoarthritis with Omron Healthcare
Future Outlook
Growth Drivers
- Increased demand due to regulatory framework improvements in regenerative medicine market
- Expansion of regenerative medicine technologies and service areas
- Growing social interest in women's medicine and egg freezing
- Strengthened collaboration with sports medicine field
- Market diversification through new expansion into animal medicine
- Technological innovation through joint research with universities and research institutions
- Strengthened partnerships with pharmaceutical companies and insurers
- Improved capital procurement capabilities through TSE Prime transition
- Overseas market development and global partnerships
- Expansion of management support services for medical institutions
Strategic Goals
- Expansion of market share in regenerative medicine-related services domestically and internationally
- Establishment of market leadership in women's medicine field
- Development of innovative products and services in animal medicine
- Commercialization of new bio-pharmaceuticals and insurance products
- Sophistication of regulatory compliance support for medical institutions
- Practical application and social implementation of sustainable regenerative medicine technologies
- Expansion of partnerships with diverse sports organizations
- Building global technology collaborations and export systems
- Leadership in industry technology and quality standards
- Establishment of cell processing technology balancing safety and efficacy
Business Segments
Regenerative Medicine-Related Outsourcing Services
- Overview
- Outsourcers cell processing necessary for regenerative medicine, and also provides regulatory compliance and management support.
- Competitiveness
- Possession of MHLW-approved specific cell processing facility and regulatory support capabilities
- Customers
-
- Orthopedic clinics
- Plastic surgery hospitals
- Obstetrics and gynecology medical institutions
- University hospitals
- Research institutions
- Products
-
- Stem cell processing outsourcing
- Blood processing outsourcing
- PFC-FD manufacturing
- Regulatory compliance consulting
- Sales of regenerative medicine-related equipment
Corporate Welfare Services
- Overview
- Provides egg freezing and health subsidies as medical support services for employees.
- Competitiveness
- Industry-first expansion of regenerative medicine services for corporate welfare
- Customers
-
- Itochu Corporation
- FamilyMart
- Don Quijote
- Uni-Charm
- Other major companies
- Products
-
- Egg freezing storage service
- Health support programs
Joint Research & Technology Development
- Overview
- Promotes joint research with major domestic universities and pharmaceutical companies to develop innovative medical technologies.
- Competitiveness
- Strong partnerships with a wide range of medical institutions and research organizations
- Customers
-
- Jichi Medical University
- Osaka University
- Juntendo University
- Rohto Pharmaceutical
- Sumitomo Life Group
- Products
-
- Exosome therapy research
- Infertility treatment technology
- Biotherapy insurance
- Stem cell processing technology
Animal Medicine Field
- Overview
- Expands business partnerships in regenerative medicine and insurance products for animals.
- Competitiveness
- Innovative medical support through collaboration with the largest pet insurance company
- Customers
-
- Anicom Holdings
- Animal hospitals
- Pet insurance providers
- Products
-
- Animal blood processing service
- Advanced medical insurance
Competitive Advantage
Strengths
- Obtained approval for MHLW specific cell processing facility
- Advanced adipose-derived stem cell processing technology
- Expertise in regenerative medicine regulatory compliance support
- Technological innovation through diverse joint research
- Stable profitable business foundation
- Extensive partnerships with sports organizations
- New market development in welfare benefits
- Expansion into animal medicine
- Diverse service offerings
- Excellent management team and specialized personnel
Competitive Advantages
- Industry-first central kitchen model achieves efficient cell processing
- Partnership network with over 1,800 medical institutions
- Differentiated cell processing system through patented technology
- Comprehensive support system including regulatory compliance
- Market penetration through medical partnerships with sports teams
- Pioneer in egg freezing services for corporate welfare
- Ongoing joint research with universities and research institutions across fields
- Uniqueness through industry collaborations for new insurance products
- Application of stem cell technology in cosmetics
- Able to invest self-funds in R&D due to profitable operations
Threats
- Business restriction risks from strengthened regenerative medicine regulations
- Technology innovation competition from rival bio companies
- Market growth slowdown or fluctuations in funding environment
- Delays in new business monetization risks
- Changes in service scope due to legal amendments
- Reduction in outsourcing from medical institutions due to infectious disease outbreaks
- Potential patent infringement issues
- Regulatory and cultural barriers in overseas expansion
- Increases in raw material and personnel costs
- Challenges in social acceptance of technology
Innovations
2024: Launch of Egg Freezing Anshin Bank Service
- Overview
- Started egg freezing storage outsourcing service for corporate welfare benefits, partnering with Itochu Corporation and others.
- Impact
- Strengthened medical support for female employees and established new revenue source
2022: Co-developed CellSource PFC-FD Insurance with Sumitomo Life
- Overview
- Developed industry-first biotherapy insurance to reduce economic burden of unapproved treatments.
- Impact
- Market penetration through sports organization memberships and customer base expansion
2021: Strategic Partnership Agreement with Wearable Cyborg HAL
- Overview
- Jointly advancing new business development in regenerative medicine with Cyberdyne.
- Impact
- Enriched services through technology integration and strengthened response to market needs
2020: Launch of PFC-FD Processing Outsourcing Service for Obstetrics and Gynecology
- Overview
- Expanded business into infertility treatment field to capture market growth.
- Impact
- Contributes to business diversification and value enhancement
2020: Started Joint Research with Osaka University Toward Establishing Exosome Therapy
- Overview
- Promotes development of new treatment methods using cell-derived vesicles.
- Impact
- Aims for early practical application of innovative medical products
Sustainability
- Strengthening and maintaining regulatory compliance system for safety assurance
- Expansion of women's medical support to meet social needs
- Promotion of healthy life expectancy extension in collaboration with medical institutions
- Social contribution through technology application in animal medicine
- Promotion of technology dissemination through partnerships with educational and research institutions
- Active participation in regional medical revitalization
- Thorough management of medical information security
- Process optimization to reduce medical waste
- Employee vocational training and occupational health & safety environment improvement
- Prompt response to amendments in bio-related regulations